Latest Insider Transactions at Vertex Pharmaceuticals Inc (VRTX)
This section provides a real-time view of insider transactions for Vertex Pharmaceuticals Inc (VRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VERTEX PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VERTEX PHARMACEUTICALS INC 's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 12
2024
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,374
-12.43%
|
$577,080
$420.24 P/Share
|
|
Feb 09
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,100
-2.97%
|
$886,200
$422.74 P/Share
|
|
Feb 09
2024
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,607
-3.95%
|
$1,100,154
$422.74 P/Share
|
|
Feb 09
2024
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,022
-2.54%
|
$853,284
$422.74 P/Share
|
|
Feb 09
2024
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
8,255
-4.84%
|
$3,483,610
$422.74 P/Share
|
|
Feb 09
2024
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,100
-4.29%
|
$886,200
$422.74 P/Share
|
|
Feb 09
2024
|
Jonathan Biller EVP and Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,588
-7.35%
|
$670,136
$422.74 P/Share
|
|
Feb 09
2024
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,177
-3.82%
|
$1,340,694
$422.74 P/Share
|
|
Feb 09
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
832
-3.34%
|
$351,104
$422.74 P/Share
|
|
Feb 09
2024
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,099
-3.97%
|
$885,778
$422.74 P/Share
|
|
Feb 09
2024
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
591
-5.08%
|
$249,402
$422.74 P/Share
|
|
Feb 09
2024
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
8,048
-20.99%
|
$3,396,256
$422.74 P/Share
|
|
Feb 08
2024
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
2,698
-6.57%
|
$1,135,858
$421.73 P/Share
|
|
Feb 07
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
BUY
Grant, award, or other acquisition
|
Direct |
7,114
+9.15%
|
-
|
|
Feb 07
2024
|
Charles F Wagner Jr EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,114
+9.72%
|
-
|
|
Feb 07
2024
|
Jeffrey M Leiden Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
7,707
+15.81%
|
-
|
|
Feb 07
2024
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
BUY
Grant, award, or other acquisition
|
Direct |
7,114
+8.2%
|
-
|
|
Feb 07
2024
|
Reshma Kewalramani CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
20,327
+10.65%
|
-
|
|
Feb 07
2024
|
Carmen Bozic EVP and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
5,928
+10.81%
|
-
|
|
Feb 07
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
BUY
Grant, award, or other acquisition
|
Direct |
4,743
+16.01%
|
-
|
|
Feb 07
2024
|
Jonathan Biller EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,743
+18.0%
|
-
|
|
Feb 07
2024
|
Kristen Ambrose SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,853
+13.73%
|
-
|
|
Feb 07
2024
|
Stuart A Arbuckle EVP, COO |
BUY
Grant, award, or other acquisition
|
Direct |
8,448
+9.22%
|
-
|
|
Feb 07
2024
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,114
+11.87%
|
-
|
|
Feb 06
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
BUY
Grant, award, or other acquisition
|
Direct |
14,842
+11.09%
|
-
|
|
Feb 06
2024
|
Charles F Wagner Jr EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,254
+12.16%
|
-
|
|
Feb 06
2024
|
Jeffrey M Leiden Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
30,916
+41.42%
|
-
|
|
Feb 06
2024
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
BUY
Grant, award, or other acquisition
|
Direct |
13,680
+9.02%
|
-
|
|
Feb 06
2024
|
Reshma Kewalramani CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
41,488
+12.88%
|
-
|
|
Feb 06
2024
|
Carmen Bozic EVP and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
13,680
+14.84%
|
-
|
|
Feb 06
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
BUY
Grant, award, or other acquisition
|
Direct |
6,260
+14.45%
|
-
|
|
Feb 06
2024
|
Jonathan Biller EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,294
+27.18%
|
-
|
|
Feb 06
2024
|
Kristen Ambrose SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,950
+23.16%
|
-
|
|
Feb 06
2024
|
Stuart A Arbuckle EVP, COO |
BUY
Grant, award, or other acquisition
|
Direct |
18,186
+11.47%
|
-
|
|
Feb 06
2024
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,680
+14.0%
|
-
|
|
Jan 08
2024
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
6,648
-73.29%
|
$2,785,512
$419.07 P/Share
|
|
Jan 02
2024
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,000
-6.42%
|
$1,215,000
$405.0 P/Share
|
|
Dec 15
2023
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
17,135
-13.62%
|
$6,973,945
$407.0 P/Share
|
|
Dec 15
2023
|
Reshma Kewalramani CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
17,135
+6.36%
|
$2,930,085
$171.55 P/Share
|
|
Dec 13
2023
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
13,354
-30.1%
|
$5,328,246
$399.8 P/Share
|
|
Dec 13
2023
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
8,603
-13.2%
|
$3,432,597
$399.0 P/Share
|
|
Dec 13
2023
|
Stuart A Arbuckle EVP, COO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,603
+11.66%
|
$1,608,761
$187.53 P/Share
|
|
Dec 13
2023
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
5,098
-4.48%
|
$2,023,906
$397.0 P/Share
|
|
Dec 05
2023
|
Nancy Thornberry Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,136
+50.0%
|
-
|
|
Nov 20
2023
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,000
-6.04%
|
$1,047,000
$349.88 P/Share
|
|
Nov 15
2023
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
35
-0.06%
|
$12,915
$369.92 P/Share
|
|
Nov 15
2023
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
19
-0.06%
|
$7,011
$369.92 P/Share
|
|
Nov 14
2023
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
5,650
-16.17%
|
$2,147,000
$380.82 P/Share
|
|
Nov 13
2023
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
5,097
-4.29%
|
$1,921,569
$377.0 P/Share
|
|
Nov 06
2023
|
Bruce I Sachs Director |
SELL
Open market or private sale
|
Direct |
11,250
-21.95%
|
$4,331,250
$385.0 P/Share
|